*863SFDAAnnals of Traditional Chinese Medicine

--- -- --

*

10

* WHO5000250ADR50ADR,1940

*

1

2 ADR3

34

(1)BMI()()

(2) 2007

(3)

(4)

(5)

1 2

3() 4(\)

5 6(\\)

1 MS() 705200638 2004 9 >810 mmolL-12 h> 1110mmolL - 1 ()OGTT

20 240 /110mmHg200410200515 ACEI

2 1: 2: 40 mg qd 3:

6:100mg 9:(NPH)6 u: 174165 /95 mmHg145 /75 mmHg 12: 16:

1234

2 (ACEI)ACEI(ARB)

CYP3A4

ICSOAPPHMDROME

.

-M.J601524550 76 1/41/85040%

2002 1. BMD2. 3. 4. 1. 2.

BMD50BMD 65BMDXDXABMDT -2.6T-2.0M.J.

M.J.OTC1500mg/dD800IU

Bisphosphonates HRT CalcitoninMiacalcin

2.IC IC

TDS Healthcare4000PharmCareCare-Trak80ICSOAP

3.SOAPS(Subjective)ADRO(Objective)A(Assessment)P(Plan)

SOAP

TITRS(Title)(Introduction)(Text)Recommendation)(Signature)

4PHMDROMEStephen C Hurley1998PHMDROME

PPatient Introduction HHealth Problem MMedications

DPharmaceutical Diagnosis RRecommended Orders ODesired Outeome ADR

MMonitoring EPatient Counseling and Education

XXX 1978 1 24 XX2007 92410:00 2007 123 XX XX (cm) 162 (kg) 53.5 (mmHg) 100/70 /78 / 18 36.8 1

520 20074B(-),200796B5-62007-9-774.5CM20+/21ERPR(++Her-2- 1

36.878/18/100/70mmHg Babinski T3N2M0A)

1CTECT 2, 3, 2974.5CM20+/21ERPR(++Her-2AECTTAC ECE-ADM110mgd1+CTX1200mgd1510 ECTTEC ECE-ADM450mg/m2LVEF10%900mg/m2

2007927 16mg + 0.9%40ml IV ST 2110mg+100ml IV ST(1) 31200mg+0.9%100ml IV ST(1) 46mg + 0.9%40ml IV QD(2) 540mg+0.9%100ml IG QD 625%2ml+10%10ml+5%500ml IG QD 7C2.0g+B60.2g++0.9%500mlIG QD 81.2g+0.9%250ml IG QD

1C4DNAmRNADNARNA 90%-(40%-45%7%-23%)

(1)()(2)(3)(4)(5)(6)(7)(8)()(9)(10) (11)(400-500mg/m2)(12)1.5109/L3.5109/L50109/L (LVEF)PEP()/LVEF7-1011-21

150%-60%10-143 260%-90% 3700-800mg/m2LVEFPEP/LVEF 1

3 420%-100%1%-60%50%25% 5(140mg/m2) 625%-100%(70%) 7

- 1 2 3CEQ10 4

1 2 3() 4 5

10.25g108 2# PO Tid 1 2 3 4 5 6 7 8 9 10 11

1

2

3

4

??

()()